US7041871B1
(en)
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US6300129B1
(en)
*
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
US5707622A
(en)
*
|
1994-03-03 |
1998-01-13 |
Genentech, Inc. |
Methods for treating ulcerative colitis
|
WO1997039772A1
(fr)
*
|
1996-04-19 |
1997-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Remede contre l'arthrite rhumatoide contenant un anticorps anti-il-8 comme principe actif
|
AU2405297A
(en)
|
1996-04-23 |
1997-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient
|
WO1997040215A1
(fr)
*
|
1996-04-23 |
1997-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Medicament contre l'infarctus du myocarde contenant comme principe actif un anticorps anti-il-8
|
US20020141988A1
(en)
*
|
1996-06-26 |
2002-10-03 |
Kouji Matsushima |
Therapeutic agent for acute lung injury resulting from indirect causes comprising anti-il-8 antibody as active ingredient
|
AU3048797A
(en)
*
|
1996-10-22 |
1998-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Sepsis remedy comprising anti-il-8 antibody as active ingredient
|
US6133426A
(en)
*
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
US6025158A
(en)
*
|
1997-02-21 |
2000-02-15 |
Genentech, Inc. |
Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
WO1998037200A2
(en)
|
1997-02-21 |
1998-08-27 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
|
DK2011514T3
(da)
|
1997-03-21 |
2012-03-26 |
Chugai Pharmaceutical Co Ltd |
Forebyggende eller terapeutisk middel til sensibiliserede-T-celle-medierede sygdomme omfattende IL-6-antagonist som en aktiv bestanddel
|
CN1326565C
(zh)
|
1997-10-14 |
2007-07-18 |
中外制药株式会社 |
淋巴细胞肿瘤抗体的增强剂
|
WO1999037779A1
(en)
*
|
1998-01-22 |
1999-07-29 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
|
US7005504B2
(en)
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
US6458355B1
(en)
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
US6468532B1
(en)
|
1998-01-22 |
2002-10-22 |
Genentech, Inc. |
Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
|
WO2000009560A2
(en)
*
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
KR100608276B1
(ko)
*
|
1998-08-24 |
2006-08-02 |
무라마쯔 다카시 |
동맥경화 및 ptca술후의 혈관 재협착에 대한예방·치료제
|
TWI248365B
(en)
|
1999-08-23 |
2006-02-01 |
Chugai Pharmaceutical Co Ltd |
HM1.24 antigen expression potentiators
|
CA2388408A1
(en)
|
1999-10-01 |
2001-04-12 |
Chugai Seiyaku Kabushiki Kaisha |
Prevention and treatment of diseases associated with blood coagulation
|
AU2001252618A1
(en)
|
2000-04-28 |
2001-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Cell proliferation inhibitors
|
EP1849479A1
(de)
|
2000-08-16 |
2007-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Linderungsmittel für Symptome infolge von Gelenkerkrankungen
|
JP3523245B1
(ja)
|
2000-11-30 |
2004-04-26 |
メダレックス,インコーポレーテッド |
ヒト抗体作製用トランスジェニック染色体導入齧歯動物
|
WO2002052005A1
(fr)
|
2000-12-22 |
2002-07-04 |
Kazusa Dna Research Institute Foundation |
Genes et proteines codees par ceux-ci
|
JP3986439B2
(ja)
|
2001-02-07 |
2007-10-03 |
中外製薬株式会社 |
造血器腫瘍の治療剤
|
CA2446968C
(en)
|
2001-05-11 |
2012-07-03 |
Kirin Beer Kabushiki Kaisha |
Human artificial chromosome containing human antibody .lambda. light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
AU2003211990A1
(en)
|
2002-02-14 |
2003-09-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing solution pharmaceuticals
|
US20070037769A1
(en)
*
|
2003-03-14 |
2007-02-15 |
Multicell Immunotherapeutics, Inc. |
Compositions and methods to treat and control tumors by loading antigen presenting cells
|
CA2479187A1
(en)
*
|
2002-03-15 |
2003-09-25 |
Astral, Inc. |
Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
|
EP2258712A3
(de)
*
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
|
CA2488441C
(en)
*
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
AU2003257536A1
(en)
|
2002-08-27 |
2004-03-19 |
Chugai Seiyaku Kabushiki Kaisha |
Method of stabilizing protein solution preparation
|
WO2004022595A1
(ja)
|
2002-09-04 |
2004-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
MRL/lprマウスを用いた抗体の作製
|
WO2004024752A1
(ja)
|
2002-09-11 |
2004-03-25 |
Chugai Seiyaku Kabushiki Kaisha |
タンパク質精製方法
|
AU2003299641C1
(en)
|
2002-12-16 |
2016-06-02 |
Cormorant Pharmaceuticals Ab |
Human monoclonal antibodies against interleukin 8 (IL-8)
|
EP1613775B1
(de)
*
|
2003-03-26 |
2012-08-29 |
Multicell Immunotherapeutics, Inc. |
Ausgewählte rna-motive zur anti-leukämie behandlung
|
ES2348008T3
(es)
|
2003-06-18 |
2010-11-26 |
Chugai Seiyaku Kabushiki Kaisha |
Transportador de fucosa.
|
KR20060069825A
(ko)
*
|
2003-08-01 |
2006-06-22 |
제넨테크, 인크. |
제한된 다양성을 갖는 항체 cdr 폴리펩티드 서열
|
WO2005014818A1
(ja)
|
2003-08-08 |
2005-02-17 |
Perseus Proteomics Inc. |
癌高発現遺伝子
|
US20050095627A1
(en)
*
|
2003-09-03 |
2005-05-05 |
The Salk Institute For Biological Studies |
Multiple antigen detection assays and reagents
|
WO2005035753A1
(ja)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
EP2311945A1
(de)
|
2003-10-14 |
2011-04-20 |
Chugai Seiyaku Kabushiki Kaisha |
Bispezifische Antikörper, die funktionale Proteine ersetzen
|
FI122368B
(fi)
*
|
2003-11-06 |
2011-12-30 |
Valtion Teknillinen |
Menetelmä huokoisen muovikalvon valmistamiseksi ja muovikalvo
|
CN101133083A
(zh)
|
2003-11-11 |
2008-02-27 |
中外制药株式会社 |
人源化的抗cd47抗体
|
UA94019C2
(ru)
|
2004-07-09 |
2011-04-11 |
Чугаи Сейяку Кабусики Кайся |
Антитело, которое специфически связывается с глипиканом 3 (gpc3)
|
US20090061485A1
(en)
|
2004-12-22 |
2009-03-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
|
PT1831258E
(pt)
|
2004-12-28 |
2016-01-07 |
Univ Genova |
Anticorpos monoclonais contra nkg2a
|
TWI544076B
(zh)
|
2005-03-31 |
2016-08-01 |
Chugai Pharmaceutical Co Ltd |
A method of manufacturing a polypeptide that controls assembly
|
CA2603264C
(en)
|
2005-04-08 |
2017-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody substituting for function of blood coagulation factor viii
|
WO2006132341A1
(ja)
|
2005-06-10 |
2006-12-14 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2部位特異的変異体
|
US8945543B2
(en)
|
2005-06-10 |
2015-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
US8952215B2
(en)
|
2005-10-18 |
2015-02-10 |
Nitto Boseki Co., Ltd. |
Antibody-producing transgenic silkworms and methods for producing the same
|
US20090291437A1
(en)
*
|
2005-11-02 |
2009-11-26 |
O'brien Sean |
Methods for targeting quadruplex sequences
|
US8679490B2
(en)
|
2005-11-07 |
2014-03-25 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
EP1973951A2
(de)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Bindende polypeptide mit eingeschränkten diversitätssequenzen
|
EP1977763A4
(de)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
Antikörper-enthaltende stabilisierende zubereitung
|
EP2009101B1
(de)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifikationsverfahren für die aufreinigung eines bispezifischen antikörpers
|
WO2007117410A2
(en)
|
2006-03-31 |
2007-10-18 |
Medarex, Inc. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
US11046784B2
(en)
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
WO2007129457A1
(ja)
|
2006-04-25 |
2007-11-15 |
The University Of Tokyo |
アルツハイマー病および癌の治療薬
|
US20100196336A1
(en)
|
2006-05-23 |
2010-08-05 |
Dongsu Park |
Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
|
MY157796A
(en)
|
2006-06-08 |
2016-07-29 |
Chugai Pharmaceutical Co Ltd |
Preventive or remedy for inflammatory disease
|
JPWO2007145227A1
(ja)
|
2006-06-14 |
2009-11-05 |
中外製薬株式会社 |
造血幹細胞増加促進剤
|
BRPI0621800B8
(pt)
|
2006-06-21 |
2022-01-04 |
Oncotherapy Science Inc |
anticorpos que se ligam à proteína fzd10, clones de hibridoma, composições farmacêuticas, kit compreendendo os referidos anticorpos, e método para diagnose ou prognose de uma doença que é associada a homólogo fzd10 ou de uma predisposição para desenvolver a doença em um indivíduo
|
ES2531933T3
(es)
*
|
2006-06-30 |
2015-03-20 |
Novo Nordisk A/S |
Anticuerpos anti-NKG2A y usos de los mismos
|
AR061986A1
(es)
|
2006-07-13 |
2008-08-10 |
Chugai Pharmaceutical Co Ltd |
Agentes inductores de muerte celular
|
EP2574625B1
(de)
|
2006-07-21 |
2015-02-25 |
HuBit genomix, Inc. |
Mittel zur Behandlung von Nierenerkrankungen
|
DE602006013809D1
(de)
|
2006-07-24 |
2010-06-02 |
Facultad De Medicina Universid |
Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden
|
WO2008020586A1
(en)
|
2006-08-14 |
2008-02-21 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibody
|
NZ576855A
(en)
|
2006-10-12 |
2012-08-31 |
Forerunner Pharma Res Co Ltd |
Diagnosis and treatment of cancer using anti-ereg antibody
|
EP2078731A4
(de)
|
2006-10-20 |
2012-08-01 |
Forerunner Pharma Res Co Ltd |
Anti-hb-egf-antikörper als wirkstoff enthaltende pharmazeutische zusammensetzung
|
CN101589059A
(zh)
|
2006-10-20 |
2009-11-25 |
株式会社未来创药研究所 |
包含抗hb-egf抗体作为活性成分的药物组合物
|
EP2103628A4
(de)
|
2006-12-14 |
2012-02-22 |
Forerunner Pharma Res Co Ltd |
Monoklonaler anti-claudin-3-antikörper und die behandlung und diagnose von krebs unter dessen verwendung
|
JP5618172B2
(ja)
|
2007-01-05 |
2014-11-05 |
国立大学法人東京大学 |
抗prg−3抗体を用いる癌の診断および治療
|
DE602008006041D1
(de)
|
2007-01-30 |
2011-05-19 |
Forerunner Pharma Res Co Ltd |
CHIMÄRER Fc GAMMA REZEPTOR UND VERFAHREN ZUR BESTIMMUNG VON ADCC-AKTIVITÄT UNTER VERWENDUNG DES REZEPTORS
|
WO2008105560A1
(ja)
|
2007-02-27 |
2008-09-04 |
Forerunner Pharma Research Co., Ltd. |
抗grp78抗体を有効成分として含む医薬組成物
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
JP5117765B2
(ja)
|
2007-05-28 |
2013-01-16 |
国立大学法人 東京大学 |
抗robo1抗体を含むpet用腫瘍診断剤
|
US8097422B2
(en)
|
2007-06-20 |
2012-01-17 |
Salk Institute For Biological Studies |
Kir channel modulators
|
US8722858B2
(en)
|
2007-06-25 |
2014-05-13 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-Prominin-1 antibody having ADCC activity or CDC activity
|
US8536313B2
(en)
|
2007-07-10 |
2013-09-17 |
Shionogi & Co., Ltd. |
Monoclonal antibody having neutralizing activity against MMP13
|
AU2008304778B9
(en)
|
2007-09-26 |
2014-05-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in CDR
|
RU2010116756A
(ru)
|
2007-09-28 |
2011-11-10 |
Чугаи Сейяку Кабусики Кайся (Jp) |
Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
|
CN106244651A
(zh)
|
2007-10-15 |
2016-12-21 |
中外制药株式会社 |
抗体的制备方法
|
EP2216344B1
(de)
|
2007-11-14 |
2017-06-28 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnose und behandlung von krebs mit einem anti-gpr49-antikörper
|
RU2559530C2
(ru)
|
2007-11-15 |
2015-08-10 |
Чугаи Сейяку Кабусики Кайся |
Моноклональные антитела, способные связываться с белком axl, и их применение
|
JP5475460B2
(ja)
|
2007-12-05 |
2014-04-16 |
中外製薬株式会社 |
掻痒症治療剤
|
RU2531521C2
(ru)
|
2007-12-05 |
2014-10-20 |
Чугаи Сейяку Кабусики Кайся |
Антитело против nr10 и его применение
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
WO2009087978A1
(ja)
|
2008-01-11 |
2009-07-16 |
The University Of Tokyo |
抗cldn6抗体
|
KR20100110864A
(ko)
*
|
2008-01-24 |
2010-10-13 |
노보 노르디스크 에이/에스 |
인간화된 항-인간 nkg2a 모노클로날 항체
|
EP3153526B1
(de)
|
2008-01-31 |
2020-09-23 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Antikörper gegen humanes cd39 und verwendung davon zur hemmung der regulatorischen t-zell-aktivität
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
EP2275443B1
(de)
|
2008-04-11 |
2015-12-02 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen bindendes molekül, das dazu in der lage ist, wiederholt zwei oder mehr antigenmoleküle zu binden
|
EP2116261A1
(de)
|
2008-05-07 |
2009-11-11 |
Institut Pasteur |
Unterbereich eines Plasmodium-Proteins mit verbessertem Impfstoff-Potenzial und medizinische Verwendungen davon
|
US9226934B2
(en)
|
2008-06-02 |
2016-01-05 |
The University Of Tokyo |
Anti-cancer drug
|
ES2575430T3
(es)
|
2008-07-10 |
2016-06-28 |
Toray Industries, Inc. |
Composición farmacéutica para el tratamiento y la prevención del cáncer
|
ES2502940T3
(es)
|
2008-08-05 |
2014-10-06 |
Toray Industries, Inc. |
Composición farmacéutica para el tratamiento y la prevención del cáncer
|
WO2010038610A1
(ja)
|
2008-09-30 |
2010-04-08 |
オリエンタル酵母工業株式会社 |
新しい軟骨細胞増殖及び分化誘導剤
|
EP2355847A1
(de)
|
2008-10-07 |
2011-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neutralisierende antikörper und fragmente davon gegen thrombozytenfaktor-4-variante 1 (pf4v1)
|
EP2359852A4
(de)
|
2008-11-17 |
2015-05-20 |
Nat Cancer Ct |
Neue auf krebs gerichtete therapie mit einem spezifisch an einen tumorstromafaktor bindenden substanzkomplex und antitumirverbindung
|
JP5756292B2
(ja)
|
2008-12-22 |
2015-07-29 |
中外製薬株式会社 |
抗hs6st2抗体及びその用途
|
US9139647B2
(en)
|
2008-12-25 |
2015-09-22 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and treatment of cancer using anti-TM4SF20 antibody
|
CA2748990A1
(en)
|
2008-12-26 |
2010-07-01 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-lgr7 antibody
|
EP2391714B2
(de)
|
2009-01-30 |
2019-07-24 |
Whitehead Institute for Biomedical Research |
Ligaturverfahren und ihre verwendung
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
US20120064096A1
(en)
|
2009-03-17 |
2012-03-15 |
Universite De La Mediterranee |
BTLA Antibodies and Uses Thereof
|
EP2899212B1
(de)
|
2009-03-30 |
2017-07-19 |
Edimer Biotech S.a. |
Herstellung von isolierten monoklonalen Agonist-Anti-EDAR-Antikörpern
|
WO2010119691A1
(ja)
|
2009-04-16 |
2010-10-21 |
国立大学法人東京大学 |
抗tmprss11e抗体を用いた癌の診断と治療
|
CA2760642A1
(en)
|
2009-05-01 |
2010-11-04 |
The University Of Tokyo |
Anti-cadherin antibody
|
WO2010131733A1
(ja)
|
2009-05-15 |
2010-11-18 |
中外製薬株式会社 |
抗axl抗体
|
WO2010137654A1
(ja)
|
2009-05-29 |
2010-12-02 |
株式会社未来創薬研究所 |
Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
|
US20120282173A1
(en)
|
2009-08-17 |
2012-11-08 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
EP2496604B1
(de)
|
2009-11-06 |
2017-08-23 |
IDEXX Laboratories, Inc. |
Antikörper gegen hunde-cd20
|
US9017669B2
(en)
|
2009-12-28 |
2015-04-28 |
Oncotherapy Science, Inc. |
Anti-CDH3 antibodies and uses thereof
|
TWI609698B
(zh)
|
2010-01-20 |
2018-01-01 |
Chugai Pharmaceutical Co Ltd |
穩定化的含抗體溶液製劑
|
HRP20211444T1
(hr)
|
2010-01-29 |
2021-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dll3 antitijelo
|
AU2010344596B2
(en)
|
2010-01-29 |
2013-08-01 |
Toray Industries, Inc. |
Polylactic acid-based resin sheet
|
RU2607366C2
(ru)
|
2010-02-04 |
2017-01-10 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или профилактики рака
|
MX340016B
(es)
|
2010-02-04 |
2016-06-22 |
Toray Industries |
Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
|
RU2603742C2
(ru)
|
2010-02-04 |
2016-11-27 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или профилактики рака
|
PL2532680T3
(pl)
|
2010-02-04 |
2015-10-30 |
Toray Industries |
Kompozycja medyczna do leczenia raka i/lub zapobiegania
|
ES2606173T3
(es)
|
2010-02-04 |
2017-03-23 |
Toray Industries, Inc. |
Composición farmacéutica para el tratamiento y/o la prevención del cáncer
|
KR101900110B1
(ko)
|
2010-02-10 |
2018-09-18 |
후지필름 알아이 파르마 가부시키가이샤 |
방사성 금속 표지 항카드헤린 항체
|
JPWO2011105573A1
(ja)
|
2010-02-26 |
2013-06-20 |
株式会社 未来創薬研究所 |
抗icam3抗体およびその用途
|
US10435458B2
(en)
|
2010-03-04 |
2019-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variants with reduced Fcgammar binding
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
WO2011140182A2
(en)
|
2010-05-04 |
2011-11-10 |
Medimmune, Llc |
Optimized degenerative muscle disease diagnostics and treatments
|
WO2011145085A2
(en)
|
2010-05-21 |
2011-11-24 |
Procognia (Israel) Ltd |
Novel antibodies and methods of use for the treatment and diagnosis of cancer
|
US9485812B2
(en)
|
2010-07-08 |
2016-11-01 |
Honda Motor Co., Ltd. |
High frequency heating coil
|
WO2012010696A1
(en)
|
2010-07-23 |
2012-01-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for cancer management targeting co-029
|
JP5843170B2
(ja)
|
2010-09-30 |
2016-01-13 |
国立研究開発法人理化学研究所 |
グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤
|
AU2011323784A1
(en)
|
2010-10-25 |
2013-05-30 |
Regents Of The University Of Minnesota |
Therapeutic composition for treatment of glioblastoma
|
PT2634194T
(pt)
|
2010-10-29 |
2018-10-19 |
Perseus Proteomics Inc |
Anticorpos anti-cdh3 possuidores de elevada capacidade de internalização
|
KR101962483B1
(ko)
|
2010-11-17 |
2019-03-29 |
추가이 세이야쿠 가부시키가이샤 |
혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
|
ES2693232T3
(es)
|
2010-11-30 |
2018-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Agente terapéutico que induce citotoxicidad
|
WO2012073992A1
(ja)
|
2010-11-30 |
2012-06-07 |
中外製薬株式会社 |
複数分子の抗原に繰り返し結合する抗原結合分子
|
WO2012080769A1
(en)
|
2010-12-15 |
2012-06-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-cd277 antibodies and uses thereof
|
ES2684602T3
(es)
|
2010-12-22 |
2018-10-03 |
Orega Biotech |
Anticuerpos contra CD39 humano y uso de los mismos
|
EP2659910B1
(de)
|
2010-12-27 |
2016-11-09 |
National University Corporation Nagoya University |
Screeningverfahren zur Identifizierung von Verbindungen die die durch Rezeptortyrosinkinase vermittelte Prosurvival-Signalisierung in Krebszellen hemmen
|
WO2012093704A1
(ja)
|
2011-01-07 |
2012-07-12 |
中外製薬株式会社 |
抗体の物性を改善させる方法
|
WO2012101125A1
(en)
|
2011-01-24 |
2012-08-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Specific antibodies against human cxcl4 and uses thereof
|
EP2487242A1
(de)
|
2011-02-09 |
2012-08-15 |
Ruprecht-Karls-Universität Heidelberg |
B-Plexin-Antagonisten und Verwendungen davon
|
KR102147548B1
(ko)
|
2011-02-25 |
2020-08-24 |
추가이 세이야쿠 가부시키가이샤 |
FcγRIIb 특이적 Fc 항체
|
AU2012233313C1
(en)
|
2011-03-30 |
2017-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for altering plasma retention and immunogenicity of antigen-binding molecule
|
EP3461846A1
(de)
|
2011-03-31 |
2019-04-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gegen icos gerichtete antikörper und verwendungen davon
|
US20140030276A1
(en)
|
2011-03-31 |
2014-01-30 |
Oriental Yeast Co., Ltd. |
Cancer immunopotentiating agent containing rankl antagonist
|
US10059746B2
(en)
|
2011-04-04 |
2018-08-28 |
University Of Iowa Research Foundation |
Methods of improving vaccine immunogenicity
|
US10006879B2
(en)
|
2011-04-12 |
2018-06-26 |
Electronic Biosciences, Inc. |
Site specific chemically modified nanopore devices
|
EP2700652B1
(de)
|
2011-04-18 |
2018-12-19 |
The University of Tokyo |
Diagnose und behandlung von krebs mittels anti-itm2a-antikörpern
|
JP2014516960A
(ja)
|
2011-05-19 |
2014-07-17 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
抗ヒトher3抗体及びその使用
|
EP2721068B1
(de)
|
2011-06-17 |
2018-12-05 |
Novo Nordisk A/S |
Selektive eliminierung erosiver zellen
|
EP2723376B1
(de)
|
2011-06-22 |
2018-12-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-axl-antikörper und verwendungen damit
|
CA2839480A1
(en)
|
2011-06-22 |
2012-12-27 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-axl antibodies and uses thereof
|
US9890218B2
(en)
|
2011-06-30 |
2018-02-13 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
EP2543677A1
(de)
|
2011-07-08 |
2013-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antikörper zur Behandlung und Vorbeugung von Thrombose
|
EP2543679A1
(de)
|
2011-07-08 |
2013-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antikörper zur Behandlung und Vorbeugung von Thrombose
|
EP2543678A1
(de)
|
2011-07-08 |
2013-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antikörper zur Behandlung und Vorbeugung von Thrombose
|
US9574005B2
(en)
|
2011-07-19 |
2017-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stable Protein-containing preparation containing argininamide or analogous compound thereof
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
MX348578B
(es)
|
2011-08-04 |
2017-06-20 |
Toray Industries |
Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
|
PL2740795T3
(pl)
|
2011-08-04 |
2017-04-28 |
Toray Industries, Inc. |
Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
|
WO2013017691A1
(en)
|
2011-08-04 |
2013-02-07 |
Medizinische Universität Innsbruck |
Cahgt1p inhibitors for use in the treatment of candidiasis
|
MX348581B
(es)
|
2011-08-04 |
2017-06-20 |
Toray Industries |
Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
|
US20140242085A1
(en)
|
2011-08-12 |
2014-08-28 |
Medical & Biological Laboratories Co., Ltd. |
Methods and composition for testing, preventing, and treating aspergillus fumigatus infection
|
EP2749572A4
(de)
|
2011-08-23 |
2015-04-01 |
Chugai Pharmaceutical Co Ltd |
Neuer anti-ddr1-antikörper mit antitumoraktivität
|
US10018630B2
(en)
|
2011-09-07 |
2018-07-10 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell isolation
|
KR102276528B1
(ko)
|
2011-09-30 |
2021-07-12 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존성 결합 분자 라이브러리
|
CN104093424A
(zh)
|
2011-09-30 |
2014-10-08 |
中外制药株式会社 |
诱导针对靶抗原的免疫应答的抗原结合分子
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
WO2013047748A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
WO2013047752A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
抗原の消失を促進する抗原結合分子
|
JP6271251B2
(ja)
|
2011-10-05 |
2018-01-31 |
中外製薬株式会社 |
糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
|
EP3603671A3
(de)
|
2011-10-28 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Krebstammzellenspezifisches molekül
|
RU2681885C2
(ru)
|
2011-10-31 |
2019-03-13 |
Чугаи Сейяку Кабусики Кайся |
Антигенсвязывающая молекула с регулируемой конъюгацией между тяжелой цепью и легкой цепью
|
WO2013081143A1
(ja)
|
2011-11-30 |
2013-06-06 |
中外製薬株式会社 |
免疫複合体を形成する細胞内への運搬体(キャリア)を含む医薬
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
EP2802602B1
(de)
|
2012-01-11 |
2019-03-27 |
Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University |
Bispezifische antkörperfragmente für neurologische krankheitsproteine und verfahren zur nutzung dieser
|
WO2013118858A1
(ja)
|
2012-02-09 |
2013-08-15 |
中外製薬株式会社 |
抗体のFc領域改変体
|
PL2818481T3
(pl)
|
2012-02-21 |
2020-02-28 |
Toray Industries, Inc. |
Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi złośliwemu
|
KR102009238B1
(ko)
|
2012-02-21 |
2019-08-09 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방용 의약 조성물
|
HUE034736T2
(en)
|
2012-02-21 |
2018-02-28 |
Toray Industries |
A pharmaceutical composition for the treatment and / or prevention of cancer
|
DK2824114T3
(da)
|
2012-02-21 |
2019-07-29 |
Toray Industries |
Farmaceutisk sammensætning til behandling af cancer
|
WO2013125667A1
(ja)
|
2012-02-24 |
2013-08-29 |
中外製薬株式会社 |
FcγRIIBを介して抗原の消失を促進する抗原結合分子
|
WO2013147153A1
(ja)
|
2012-03-29 |
2013-10-03 |
株式会社未来創薬研究所 |
抗lamp5抗体およびその利用
|
CN104203281B
(zh)
|
2012-03-30 |
2019-07-26 |
东丽株式会社 |
胆囊癌的治疗和/或预防用药物组合物
|
CA2869120C
(en)
|
2012-03-30 |
2023-05-23 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of liver cancer
|
CA2869704A1
(en)
|
2012-04-04 |
2013-10-10 |
Perseus Proteomics Inc. |
Drug conjugate comprising anti-cdh3 (pcadherin) antibody
|
CA2871417C
(en)
|
2012-04-23 |
2021-08-31 |
Genefrontier Corporation |
Anti-human cd69 antibody, and use thereof for medical purposes
|
EP2848633B1
(de)
|
2012-05-11 |
2019-02-06 |
Microbial Chemistry Research Foundation |
Anti-cxadr-antikörper
|
CN107964042B
(zh)
|
2012-05-30 |
2022-04-19 |
中外制药株式会社 |
靶组织特异性抗原结合分子
|
DK2857419T3
(da)
|
2012-05-30 |
2021-03-29 |
Chugai Pharmaceutical Co Ltd |
Antigen-bindende molekyle til eliminering af aggregerede antigener
|
EP2862875B1
(de)
|
2012-06-14 |
2023-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindendes molekül mit modifizierter fc-region
|
EP2861998B1
(de)
|
2012-06-18 |
2020-07-22 |
Electronic Biosciences Inc. |
Zellfreie testvorrichtung und verfahren zur verwendung
|
WO2014001368A1
(en)
|
2012-06-25 |
2014-01-03 |
Orega Biotech |
Il-17 antagonist antibodies
|
EP2881467B1
(de)
|
2012-07-30 |
2018-10-31 |
National University Corporation Nagoya University |
Monoklonaler antikörper gegen menschlichen midkine
|
EP2889376A4
(de)
|
2012-08-24 |
2016-11-02 |
Chugai Pharmaceutical Co Ltd |
Maus-fc-rii-spezifischer fc-antikörper
|
TW202237660A
(zh)
|
2012-08-24 |
2022-10-01 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
US9695247B2
(en)
|
2012-09-03 |
2017-07-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies directed against ICOS for treating graft-versus-host disease
|
CN104797132B
(zh)
|
2012-09-13 |
2017-06-30 |
中外制药株式会社 |
基因敲入非人动物
|
RU2673943C2
(ru)
|
2012-09-27 |
2018-12-03 |
Чугаи Сейяку Кабусики Кайся |
Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него
|
BR112015006634B1
(pt)
|
2012-09-28 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Método e kit para avaliação de reação de coagulação sanguínea
|
JP6361003B2
(ja)
|
2012-11-09 |
2018-07-25 |
ジーンフロンティア株式会社 |
癌治療のための抗adam28抗体
|
EP2733153A1
(de)
|
2012-11-15 |
2014-05-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur Herstellung von Immunkonjugaten und Verwendungen davon
|
LT3199552T
(lt)
|
2012-11-20 |
2020-04-10 |
Sanofi |
Anti-ceacam5 antikūnai ir jų panaudojimas
|
EP3400961B1
(de)
|
2012-12-27 |
2021-02-24 |
Sanofi |
Anti-lamp1 antikörper und antikörper-konjugate und deren verwendung
|
CN105102618B
(zh)
|
2012-12-27 |
2018-04-17 |
中外制药株式会社 |
异源二聚化多肽
|
EP2955226B1
(de)
|
2013-02-08 |
2019-06-26 |
Medical & Biological Laboratories Co., Ltd. |
Antikörper gegen humanes nrg1-protein
|
WO2014126198A1
(ja)
|
2013-02-15 |
2014-08-21 |
株式会社ペルセウスプロテオミクス |
抗cdh3ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用
|
EP3339327A3
(de)
|
2013-02-28 |
2018-09-19 |
National Cancer Center |
Antikörper gegen unlösliches fibrin
|
CN113621057A
(zh)
|
2013-04-02 |
2021-11-09 |
中外制药株式会社 |
Fc区变体
|
WO2014174596A1
(ja)
|
2013-04-23 |
2014-10-30 |
株式会社医学生物学研究所 |
ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
|
CN107095872A
(zh)
|
2013-05-16 |
2017-08-29 |
国立大学法人京都大学 |
用于确定癌症预后的方法
|
US10005839B2
(en)
|
2013-05-17 |
2018-06-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antagonist of the BTLA/HVEM interaction for use in therapy
|
CA2916362A1
(en)
|
2013-06-24 |
2014-12-31 |
Masami Suzuki |
Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
|
WO2015020212A1
(ja)
|
2013-08-09 |
2015-02-12 |
東レ株式会社 |
癌の治療及び/又は予防用医薬組成物
|
EP3047857A4
(de)
|
2013-09-20 |
2017-08-09 |
Chugai Seiyaku Kabushiki Kaisha |
Behandlung von hämorrhagischen erkrankungen durch anti-protein-c-antikörper
|
RU2758952C1
(ru)
|
2013-09-27 |
2021-11-03 |
Чугаи Сейяку Кабусики Кайся |
Способ получения полипептидного гетеромультимера
|
LT3057992T
(lt)
|
2013-10-15 |
2024-07-25 |
Genefrontier Corporation |
Žmogaus antikūnas prieš agrekanazės tipo adamts rūšis, skirtas terapiniams preparatams nuo ligų, susijusių su agrekanaze
|
EP3070167A4
(de)
|
2013-11-06 |
2017-06-07 |
Osaka University |
Antikörper mit breiter neutralisierender aktivität bei einem gruppe-1-influenza-a-virus
|
RU2704228C2
(ru)
|
2013-11-07 |
2019-10-24 |
Инсерм (Институт Насьональ Де Ла Сант Эт Де Ла Решерш Медикаль) |
Неконкурентные в отношении нейрегулина аллостерические антитела против человеческого her3 и их применения
|
US20160280787A1
(en)
|
2013-11-11 |
2016-09-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified antibody variable region
|
CA2931296C
(en)
|
2013-12-04 |
2024-04-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
|
CN105849562B
(zh)
|
2013-12-24 |
2019-08-16 |
中外制药株式会社 |
可溶性gpc3蛋白质的测定方法
|
NZ722057A
(en)
|
2013-12-27 |
2022-10-28 |
Chugai Pharmaceutical Co Ltd |
Method for purifying antibody having low isoelectric point
|
EP3087986B1
(de)
|
2013-12-27 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Mutantes fgfr-gatekeeper-gen und dagegen gerichteter wirkstoff
|
EP3572093A1
(de)
|
2014-03-31 |
2019-11-27 |
Debiopharm International SA |
Fgfr-fusionen
|
US10544231B2
(en)
|
2014-04-16 |
2020-01-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies for the prevention or the treatment of bleeding episodes
|
TWI831106B
(zh)
|
2014-06-20 |
2024-02-01 |
日商中外製藥股份有限公司 |
用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
|
US10166304B2
(en)
|
2014-07-11 |
2019-01-01 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
US20170362304A1
(en)
|
2014-08-20 |
2017-12-21 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring viscosity of protein solution
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
UA127961C2
(uk)
|
2014-12-19 |
2024-02-28 |
Чугей Сейяку Кабусікі Кайся |
Антитіло до латентного міостатину
|
TN2018000324A1
(en)
|
2015-01-23 |
2020-01-16 |
Sanofi Sa |
ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123
|
JP2018510842A
(ja)
|
2015-02-05 |
2018-04-19 |
中外製薬株式会社 |
イオン濃度依存的抗原結合ドメインを含む抗体、Fc領域改変体、IL−8に結合する抗体、およびその使用
|
WO2016128349A1
(en)
|
2015-02-09 |
2016-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
|
EP3280455A1
(de)
|
2015-04-07 |
2018-02-14 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Nichtinvasive abbildung von tumor pd-l1 expression
|
AU2016248817A1
(en)
|
2015-04-17 |
2017-08-17 |
F. Hoffmann-La Roche Ag |
Combination therapy with coagulation factors and multispecific antibodies
|
WO2017005847A1
(en)
|
2015-07-07 |
2017-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to myosin 18a and uses thereof
|
EP3331569A1
(de)
|
2015-08-07 |
2018-06-13 |
Gamamabs Pharma |
Antikörper, antikörper-wirkstoff-konjugate und verfahren zur verwendung
|
RU2728430C2
(ru)
*
|
2015-09-18 |
2020-07-29 |
Чугаи Сейяку Кабусики Кайся |
Il-8-связывающие антитела и их применения
|
ES2941968T3
(es)
|
2015-10-01 |
2023-05-29 |
The Whitehead Institute For Biomedical Res |
Marcaje de anticuerpos
|
KR20180069839A
(ko)
|
2015-10-08 |
2018-06-25 |
자임워크스 인코포레이티드 |
카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
EP3370763B1
(de)
|
2015-11-03 |
2024-04-10 |
Regents of the University of Minnesota |
Cd200-hemmer und verfahren zur verwendung
|
EP3378488A4
(de)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur verbesserung der humoralen immunreaktion
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
WO2017110980A1
(ja)
|
2015-12-25 |
2017-06-29 |
中外製薬株式会社 |
増強された活性を有する抗体及びその改変方法
|
US11359009B2
(en)
|
2015-12-25 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
WO2017144668A1
(en)
|
2016-02-26 |
2017-08-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity for btla and uses thereof
|
US11072666B2
(en)
|
2016-03-14 |
2021-07-27 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
CA3007135A1
(en)
|
2016-03-23 |
2017-09-28 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Novel anti-pd-l1 antibodies
|
MX2018011109A
(es)
|
2016-03-28 |
2018-11-09 |
Toray Industries |
Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
|
BR112019001693A2
(pt)
|
2016-07-29 |
2019-07-02 |
Ct Hospitalier Universitaire Toulouse |
anticorpos direcionados a macrófagos associados a tumores e seus usos
|
TWI831965B
(zh)
|
2016-08-05 |
2024-02-11 |
日商中外製藥股份有限公司 |
Il-8相關疾病之治療用或預防用組成物
|
CN109661241A
(zh)
|
2016-09-06 |
2019-04-19 |
中外制药株式会社 |
使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
BR112019008335A2
(pt)
|
2016-10-28 |
2020-01-28 |
Toray Industries |
conjugado de um anticorpo, composição farmacêutica e método para o tratamento e/ou a prevenção de um câncer
|
WO2018091720A1
(en)
|
2016-11-21 |
2018-05-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the prophylactic treatment of metastases
|
MX2019005947A
(es)
|
2016-11-28 |
2019-08-26 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a ligando que tiene actividad de union a ligando ajustable.
|
WO2018106931A1
(en)
|
2016-12-07 |
2018-06-14 |
Progenity Inc. |
Gastrointestinal tract detection methods, devices and systems
|
US10980739B2
(en)
|
2016-12-14 |
2021-04-20 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
WO2018158398A1
(en)
|
2017-03-02 |
2018-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
EP3596126A4
(de)
|
2017-03-15 |
2021-03-03 |
Tsinghua University |
Neuartige anti-trkb-antikörper
|
CN110382544B
(zh)
|
2017-03-16 |
2023-12-22 |
先天制药公司 |
用于治疗癌症的组合物和方法
|
AU2018240938A1
(en)
|
2017-03-24 |
2019-10-10 |
Zenyaku Kogyo Co., Ltd. |
Anti-IgM/B cell surface antigen bispecific antibody
|
EP3603670A4
(de)
|
2017-03-31 |
2021-03-10 |
Public University Corporation Nara Medical University |
Medizinische zusammensetzung zur prävention und/oder behandlung von blutgerinnungsfaktor-ix-anomalie mit einer multispezifischen antigenbindenden molekülersatzfunktion des blutgerinnungsfaktors viii
|
CN118453852A
(zh)
|
2017-04-14 |
2024-08-09 |
埃克塞里艾克西斯公司 |
用于预防或治疗癌症的amhrii结合化合物
|
CN110944665B
(zh)
|
2017-04-14 |
2024-04-19 |
埃克塞里艾克西斯公司 |
用于预防或治疗肺癌的amhrii结合化合物
|
JP7261739B2
(ja)
|
2017-04-27 |
2023-04-20 |
中外製薬株式会社 |
薬物動態が改善された血液凝固第ix因子
|
WO2019020480A1
(en)
|
2017-07-24 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
|
US11085929B2
(en)
|
2017-08-31 |
2021-08-10 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Nanoshell-structured material as co-matrix for peptide characterization in mass spectrometry
|
KR20200133323A
(ko)
|
2017-09-21 |
2020-11-27 |
임체크 테라퓨틱스 에스에이에스 |
Btn2에 대해 특이성을 갖는 항체 및 이의 용도
|
AU2018359218B2
(en)
|
2017-11-01 |
2021-11-11 |
Nantbio, Inc. |
IL8 blocking EMT pathway and overcoming cancer stem cells
|
CA3083346A1
(en)
|
2017-11-28 |
2019-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand-binding activity
|
TWI817974B
(zh)
|
2017-12-28 |
2023-10-11 |
日商中外製藥股份有限公司 |
細胞毒性誘導治療劑
|
JP2021510697A
(ja)
|
2018-01-12 |
2021-04-30 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
がん処置のための坑il−8抗体及び坑pd−1抗体を用いる組合せ治療
|
WO2019177543A1
(en)
|
2018-03-15 |
2019-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
AU2019243764A1
(en)
|
2018-03-28 |
2020-11-05 |
Mitsubishi Tanabe Pharma Corporation |
Drug conjugates of cMET monoclonal binding agents, and uses thereof
|
CA3095719A1
(en)
|
2018-03-30 |
2019-10-03 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of cancer
|
US20210196568A1
(en)
|
2018-05-21 |
2021-07-01 |
Chugai Seiyaku Kabushiki Kaisha |
Lyophilized formulation sealed in glass container
|
CA3102060A1
(en)
|
2018-05-31 |
2019-12-05 |
Shionogi & Co., Ltd. |
Nav1.7 monoclonal antibody
|
DK3807316T3
(da)
|
2018-06-18 |
2024-07-29 |
Innate Pharma |
Sammensætninger og fremgangsmåder til behandling af cancer
|
US20210308170A1
(en)
|
2018-07-27 |
2021-10-07 |
Osaka University |
Composition for suppression of aging, prevention, amelioration, or treatment of an age-related disease or symptom, or extension of lifespan
|
WO2020059847A1
(ja)
|
2018-09-21 |
2020-03-26 |
国立大学法人 東京医科歯科大学 |
ヒトhmgb1に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
|
EP3877413A1
(de)
|
2018-11-06 |
2021-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von akuter myeloischer leukämie durch vernichtung von leukämischen stammzellen
|
CN116726361A
(zh)
|
2018-11-19 |
2023-09-12 |
比奥拉治疗股份有限公司 |
用生物治疗剂治疗疾病的方法和装置
|
JP2022516408A
(ja)
|
2018-12-14 |
2022-02-28 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
単離されたMHC由来ヒトペプチドおよびCD8+CD45RClowTregの抑制機能を刺激し、かつ活性化するためのその使用
|
CN113260381A
(zh)
|
2018-12-27 |
2021-08-13 |
盐野义制药株式会社 |
新型抗ccr8抗体
|
US11680105B2
(en)
|
2019-01-17 |
2023-06-20 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
US20220089770A1
(en)
|
2019-01-24 |
2022-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Novel cancer antigens and antibodies of said antigens
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
CA3130909A1
(en)
|
2019-02-28 |
2020-09-03 |
Juntendo Educational Foundation |
Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
|
US20220153875A1
(en)
|
2019-03-19 |
2022-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
|
JP2022525937A
(ja)
|
2019-03-20 |
2022-05-20 |
イムチェック セラピューティクス エスエーエス |
Btn2に対する特異性を有する抗体及びその使用
|
EP3947446A1
(de)
|
2019-03-25 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Behandlung von tauopathie-erkrankungen durch abzielen auf neue tau-spezies
|
AU2020273072A1
(en)
|
2019-04-10 |
2021-12-09 |
Chugai Seiyaku Kabushiki Kaisha |
Method for purifying Fc region-modified antibody
|
AU2020258025A1
(en)
|
2019-04-18 |
2021-11-25 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
US20220324975A1
(en)
|
2019-06-05 |
2022-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody cleavage site binding molecule
|
EP4007775A1
(de)
|
2019-08-02 |
2022-06-08 |
Orega Biotech |
Neue il-17b-antikörper
|
WO2021058763A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance antibodies and uses thereof
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
EP3812008A1
(de)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-kompetitiver antagonistischer antikörper
|
JP2023503429A
(ja)
|
2019-11-22 |
2023-01-30 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白血病幹細胞を根絶することによる、急性骨髄性白血病の処置のための、アドレノメデュリン阻害剤
|
WO2021110995A1
(en)
|
2019-12-04 |
2021-06-10 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
EP3870261B1
(de)
|
2019-12-13 |
2024-01-31 |
Biora Therapeutics, Inc. |
Einnehmbare vorrichtung zur abgabe eines therapeutischen mittels an den magen-darm-trakt
|
CA3169521A1
(en)
|
2020-02-28 |
2021-09-02 |
Marie-Priscille Brun |
Modified binding polypeptides for optimized drug conjugation
|
WO2021175954A1
(en)
|
2020-03-04 |
2021-09-10 |
Imcheck Therapeutics Sas |
Antibodies having specificity for btnl8 and uses thereof
|
EP4119158A4
(de)
|
2020-03-12 |
2024-05-08 |
Toray Industries, Inc. |
Medikament zur behandlung und/oder prävention von krebs
|
US20230139178A1
(en)
|
2020-03-12 |
2023-05-04 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
JPWO2021182572A1
(de)
|
2020-03-12 |
2021-09-16 |
|
|
JPWO2021182573A1
(de)
|
2020-03-12 |
2021-09-16 |
|
|
KR20220151684A
(ko)
|
2020-03-12 |
2022-11-15 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
CN115335082A
(zh)
|
2020-03-27 |
2022-11-11 |
光爱科技公司 |
用于杀死肿瘤细胞的医药品
|
WO2021200131A1
(ja)
|
2020-03-30 |
2021-10-07 |
国立研究開発法人国立がん研究センター |
抗体薬物複合体
|
JPWO2021206078A1
(de)
|
2020-04-06 |
2021-10-14 |
|
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
WO2021214222A1
(en)
|
2020-04-24 |
2021-10-28 |
Sanofi |
Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
|
JP2023522393A
(ja)
|
2020-04-24 |
2023-05-30 |
サノフイ |
抗ceacam5抗体コンジュゲートおよびセツキシマブを含有する抗腫瘍組み合わせ
|
JP2023522392A
(ja)
|
2020-04-24 |
2023-05-30 |
サノフイ |
抗ceacam5抗体コンジュゲートおよびフォルフィリを含有する抗腫瘍組み合わせ
|
IL297311A
(en)
|
2020-04-24 |
2022-12-01 |
Sanofi Sa |
Antitumor combinations containing conjugates of antibodies to ceacam5 and folfox
|
JP2023525053A
(ja)
|
2020-05-12 |
2023-06-14 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
皮膚t細胞リンパ腫及びtfh由来リンパ腫を処置する新しい方法
|
WO2021235537A1
(ja)
|
2020-05-22 |
2021-11-25 |
中外製薬株式会社 |
凝固第viii因子(f.viii)機能代替活性を有する物質を中和する抗体
|
JPWO2021261546A1
(de)
|
2020-06-24 |
2021-12-30 |
|
|
US20230256092A1
(en)
|
2020-06-30 |
2023-08-17 |
Shionogi & Co., Ltd. |
Combined use of anti-ccr8 antibody and chemotherapeutic agent
|
CN116194473A
(zh)
|
2020-07-28 |
2023-05-30 |
中外制药株式会社 |
包含新改造型抗体的具备针护罩的带针预充注射器制剂
|
CN116194124A
(zh)
|
2020-07-31 |
2023-05-30 |
中外制药株式会社 |
包含表达嵌合受体的细胞的药物组合物
|
JP2023540732A
(ja)
|
2020-09-04 |
2023-09-26 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗ceacam5抗体及びコンジュゲート並びにそれらの使用
|
EP3981789A1
(de)
|
2020-10-12 |
2022-04-13 |
Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives |
Anti-lilrb-antikörper und verwendungen davon
|
EP4229082A1
(de)
|
2020-10-16 |
2023-08-23 |
AC Immune SA |
Alpha-synuclein bindende antikörper zur therapie und diagnose
|
JPWO2022124247A1
(de)
|
2020-12-09 |
2022-06-16 |
|
|
TW202242118A
(zh)
|
2020-12-18 |
2022-11-01 |
瑞士商Ac 免疫有限公司 |
抗體遞送
|
EP4281187A1
(de)
|
2021-01-20 |
2023-11-29 |
Bioentre LLC |
Ctla4-bindende proteine und verfahren zur behandlung von krebs
|
CN117545508A
(zh)
|
2021-06-23 |
2024-02-09 |
东丽株式会社 |
用于癌的治疗和/或预防的药品
|
EP4360649A1
(de)
|
2021-06-23 |
2024-05-01 |
Toray Industries, Inc. |
Medikament zur behandlung und/oder prävention von krebs
|
MX2024001104A
(es)
|
2021-07-27 |
2024-02-23 |
Toray Industries |
Medicamento para el tratamiento y/o prevencion de cancer.
|
KR20240041917A
(ko)
|
2021-07-27 |
2024-04-01 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
EP4378477A1
(de)
|
2021-07-27 |
2024-06-05 |
Toray Industries, Inc. |
Medikament zur behandlung und/oder prävention von krebs
|
KR20240095160A
(ko)
|
2021-07-29 |
2024-06-25 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
인간화된 항-인간 βig-h3 단백질 및 이의 용도
|
JP2024530943A
(ja)
|
2021-08-06 |
2024-08-27 |
アンスティテュ・レジオナル・デュ・カンセール・ドゥ・モンペリエ |
がんの処置のための方法
|
WO2023033129A1
(ja)
|
2021-09-03 |
2023-03-09 |
東レ株式会社 |
癌の治療及び/又は予防用医薬組成物
|
CN117999098A
(zh)
|
2021-09-24 |
2024-05-07 |
光爱科技公司 |
用于杀死肿瘤细胞的医药品
|
CN118043031A
(zh)
|
2021-10-04 |
2024-05-14 |
诺华股份有限公司 |
表面活性剂稳定剂
|
TW202333781A
(zh)
|
2021-10-08 |
2023-09-01 |
日商中外製藥股份有限公司 |
抗hla-dq2﹒5抗體製劑
|
MX2024004393A
(es)
|
2021-11-01 |
2024-04-30 |
Shionogi & Co |
Nuevo anticuerpo monoclonal nav1.7.
|
KR20240099412A
(ko)
|
2021-11-05 |
2024-06-28 |
사노피 |
항-ceacam5 항체-약물 접합체 및 항-vegfr-2 항체를 함유하는 항종양 조합
|
CN115466331B
(zh)
|
2021-11-18 |
2023-05-30 |
合源生物科技(天津)有限公司 |
靶向bcma的嵌合抗原受体及其应用
|
WO2023100975A1
(ja)
|
2021-12-01 |
2023-06-08 |
中外製薬株式会社 |
抗体含有製剤の調製方法
|
AU2023230951A1
(en)
|
2022-03-09 |
2024-09-05 |
Merck Patent Gmbh |
Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
|
AR128745A1
(es)
|
2022-03-09 |
2024-06-12 |
Merck Patent Gmbh |
Anticuerpos y conjugados anti-ceacam5 y usos de los mismos
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
WO2023240287A1
(en)
|
2022-06-10 |
2023-12-14 |
Bioentre Llc |
Combinations of ctla4 binding proteins and methods of treating cancer
|
WO2024056668A1
(en)
|
2022-09-12 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
New anti-itgb8 antibodies and its uses thereof
|
WO2024180192A1
(en)
|
2023-03-01 |
2024-09-06 |
Sanofi |
Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5
|
EP4427763A1
(de)
|
2023-03-06 |
2024-09-11 |
Sanofi |
Antitumorkombinationen mit anti-ceacam5-antikörper-wirkstoff-konjugaten, anti-vegfr-2-antikörpern und anti-pd1/pd-l1-antikörpern
|